Compare Nutrien Ltd (NTR) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nutrien Ltd vs Regeneron Pharmaceuticals Inc — how do they compare? Nutrien Ltd trades at $66.8 (market cap $31.67B), while Regeneron Pharmaceuticals Inc trades at $673.67 (market cap $70.47B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 2.2× Nutrien Ltd's market cap, and Nutrien Ltd pays the higher dividend (3.3%). Which is the better fit depends on your goals.
| NTR | REGN | |
|---|---|---|
Market Cap | $31.67B | $70.47B |
Sector | Basic Materials | Health |
52-Week High | $83.94 | $812.27 |
52-Week Low | $53.64 | $545.46 |
Enterprise Value | $44.84B | $64.42B |
Dividend Yield | 3.3% | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nutrien (NTR) trades at $66.84, down 0.65% with neutral technical signals. The company shows improving fundamentals with Q1 2026 earnings beat and projected revenue growth to $27.8B in 2026. Valuation appears reasonable with P/E of 13.58 and P/S of 1.16. Recent institutional buying activity and a $0.55 dividend payment scheduled for July 2026 provide additional investor appeal.
The outlook remains positive with strong analyst consensus (60.6% buy ratings) and $77.67 price target suggesting 16% upside. Key risks include volatile input costs and fertilizer market dynamics. The combination of reasonable valuation, earnings momentum, and institutional support positions NTR favorably for long-term investors despite near-term market volatility.
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
